LENZ Therapeutics, Inc.
LENZ · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $15,000 | $0 |
| % Growth | – | -100% | – | – |
| Cost of Goods Sold | $58 | $0 | $0 | $734 |
| Gross Profit | -$58 | $0 | $15,000 | -$734 |
| % Margin | – | – | 100% | – |
| R&D Expenses | $29,801 | $59,504 | $21,125 | $37,932 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $28,751 | $12,925 | $4,358 | $21,777 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $58,552 | $72,429 | $25,483 | $59,709 |
| Operating Income | -$58,610 | -$72,429 | -$10,483 | -$60,443 |
| % Margin | – | – | -69.9% | – |
| Other Income/Exp. Net | $8,842 | $2,282 | $19 | -$10,317 |
| Pre-Tax Income | -$49,768 | -$70,147 | -$10,464 | -$70,760 |
| Tax Expense | $1 | -$179 | $347 | $0 |
| Net Income | -$49,769 | -$69,968 | -$10,811 | -$70,760 |
| % Margin | – | – | -72.1% | – |
| EPS | -2.34 | -15.3 | -12.891 | -8.538 |
| % Growth | 84.7% | -18.7% | -51% | – |
| EPS Diluted | -2.34 | -15.3 | -12.891 | -8.538 |
| Weighted Avg Shares Out | 21,281 | 8,145 | 7,839 | 8,287 |
| Weighted Avg Shares Out Dil | 21,281 | 8,145 | 7,839 | 8,287 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,553 | $2,189 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $58 | $15 | $8 | $734 |
| EBITDA | -$49,710 | -$72,414 | -$10,475 | -$70,026 |
| % Margin | – | – | -69.8% | – |